ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Drug pageFormoterol: every studyMany companies study it; this page follows only the 137 they lead. All 190 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceutici200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatrisits history only160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharmaits history only60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharmaits history only30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead

Also a collaborator on its studies: Parexel, CISCRP, eResearchTechnology, Menarini Group, Integrated Therapeutics Group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chiesi Farmaceutici only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Oct 30, 2006.

  1. Sep 3, 2009Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT00972140 · 457 enrolled · Poland
  2. Nov 29, 2010Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01344655 · 16 enrolled · United Kingdom
  3. Apr 21, 20112 phase 2 studiesNCT01343745, NCT01349257
  4. Jun 9, 2011Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT01398111 · 44 enrolled · Belgium
  5. Oct 11, 2011Phase 3 study in AsthmaNCT01475032 · 638 enrolled · Bulgaria, France, Germany and more
  6. Apr 23, 2012Phase 2 study in AsthmaNCT01584492 · 59 enrolled · Poland, Ukraine
  7. Aug 3, 2012Phase 3 study in Asthma in ChildrenNCT01658891 · Denmark
  8. Aug 5, 2013Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT01917331 · 1,368 enrolled · Hungary
  9. Jan 9, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02040597 · 42 enrolled · Poland
  10. Apr 11, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02119234 · 36 enrolled · Poland
  11. Nov 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02975843 · 28 enrolled
  12. Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03268226 · 20 enrolled · Belgium, Hungary
  13. May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04876677 · 25 enrolled · Belgium, Hungary
  14. Mar 4, 2022Phase 3 study in AsthmaNCT05292586 · 1,377 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 Chiesi Farmaceutici leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05292586Asthma · United States3CompletedJun 24, 20241,377
NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedJan 3, 202225
NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedJan 30, 201920
NCT02975843Pulmonary Disease, Chronic Obstructive1CompletedMar 21, 201728
NCT02119234Pulmonary Disease, Chronic Obstructive · Poland1CompletedFeb 201536
NCT02040597Pulmonary Disease, Chronic Obstructive · Poland1CompletedApr 201542
NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary3CompletedJan 14, 20161,368
NCT01658891Asthma in Children · Denmark3WithdrawnNov 20150
NCT01584492Asthma · Poland, Ukraine2CompletedFeb 201359
NCT01475032Asthma · Bulgaria, France, Germany and more3CompletedSep 2012638
NCT01398111Pulmonary Disease, Chronic Obstructive · Belgium1CompletedAug 201144
NCT01349257Asthma · United Kingdom2CompletedJun 201124
NCT01343745Mild Persistent Asthma · United Kingdom2CompletedAug 200818
NCT01344655Pulmonary Disease, Chronic Obstructive · United Kingdom4CompletedSep 201216
NCT00972140Pulmonary Disease, Chronic Obstructive · Poland3CompletedApr 2006457
NCT00861926Asthma · Bulgaria, Croatia, Czechia and more3CompletedDec 7, 20101,714
NCT00742248Pulmonary Disease, Chronic Obstructive · Italy2CompletedMay 200554
NCT00476099Pulmonary Disease, Chronic Obstructive · France3CompletedAug 2008828
NCT00413387Asthma · Austria, Poland, Ukraine3CompletedAug 2005219
NCT00394368Asthma · Poland, Ukraine3Completed180

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.